Astrazeneca PLC (NYSE:AZN) Latest News, Stock Price and Trading Information

FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure

Business Wire 20-Aug 7:00 AM

CALQUENCE (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia

Business Wire 14-Aug 8:00 AM

LYNPARZA (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer

Business Wire 14-Aug 7:00 AM

TAGRISSO (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer

Business Wire 9-Aug 7:00 AM

Myriad Will Seek FDA Approval of BRACAnalysis CDx As a Companion Diagnostic for Lynparza (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

Globe Newswire 7-Aug 7:05 AM

LYNPARZA (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

Business Wire 7-Aug 6:55 AM

BioCardia Signs Exclusive Development Agreement With AstraZeneca

Globe Newswire 25-Jul 6:00 AM

Proteostasis Therapeutics Announces Management Changes and Appointments

PRNewswire 23-Jul 7:00 AM

IMFINZI (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer

Business Wire 22-Jul 8:00 AM

Foundation Medicine Expands Indication for FoundationOneCDx as a Companion Diagnostic for LYNPARZA (Olaparib)

Business Wire 1-Jul 3:30 PM

IMFINZI (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer

Business Wire 27-Jun 8:56 AM

Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis Diagnostic System in Japan

Globe Newswire 19-Jun 7:05 AM